Pfizer expects to produce 80mln courses of COVID-19 antiviral pill: CNBC reporter tweet

Earlier this month, Pfizer said it expects to manufacture 180,000 treatment courses by the end of this year

  
Image used for illustrative purpose Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021.

Image used for illustrative purpose Syringe and vial are seen in front of displayed new Pfizer logo in this illustration taken, June 24, 2021.

REUTERS/Dado Ruvic/Illustration

Pfizer Inc now expects to manufacture 80 million treatment courses of its experimental COVID-19 antiviral drug, up from a previous forecast of 50 million, Chief Executive Officer Albert Bourla said in a CNBC interview on Monday.

Earlier this month, Pfizer said it expects to manufacture 180,000 treatment courses by the end of this year and at least 50 million courses by the end of next year, including 21 million in the first half of 2022.

"We can right now commit to 80 million doses ... thanks to our manufacturing machine," Bourla told CNBC.

Bourla said he was confident that the drug, with the brand name Paxlovid, would be unaffected by the Omicron variant of the coronavirus.

Adding that the company would know more details about the new variant in the next few weeks.

Pfizer applied for emergency authorization of Paxlovid last week after reporting data showing that it was 89% effective at preventing hospitalization or death in at-risk people.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Maju Samuel) ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325))